Thermo Fisher Scientific Inc. $TMO Shares Sold by Railway Pension Investments Ltd

Key Points

• Railway Pension Investments Ltd. reduced its Thermo Fisher Scientific stake by 12.2% in the second quarter, selling 49,960 shares. It still held 358,970 shares valued at approximately $180 million, representing 2.3% of its portfolio.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $619.41. TMO shares opened at $618.83, near the consensus target and below the 12-month high of $647.
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, beating expectations, while revenue grew 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share, although insiders sold roughly $44.1 million of stock over the past 90 days.

Railway Pension Investments Ltd trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 358,970 shares of the medical research company's stock after selling 49,960 shares during the quarter. Thermo Fisher Scientific accounts for approximately 2.3% of Railway Pension Investments Ltd's investment portfolio, making the stock its 16th biggest holding. Railway Pension Investments Ltd owned 0.10% of Thermo Fisher Scientific worth $179,973,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. J. Stern & Co. LLP increased its holdings in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock valued at $18,258,082,000 after purchasing an additional 31,455,105 shares in the last quarter. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific during the second quarter worth $15,501,867,000. State Street Corp grew its position in Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after buying an additional 229,630 shares during the period. Corient Private Wealth LP purchased a new position in Thermo Fisher Scientific in the second quarter valued at $382,547,000. Finally, Capital World Investors raised its position in shares of Thermo Fisher Scientific by 7.0% in the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TMO. Royal Bank Of Canada upped their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a report on Friday, July 24th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research report on Monday, July 6th. Jefferies Financial Group reaffirmed a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Finally, Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $618.83 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market capitalization of $228.81 billion, a PE ratio of 33.29, a price-to-earnings-growth ratio of 2.53 and a beta of 0.84. The firm's 50-day moving average is $561.73 and its two-hundred day moving average is $512.40. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analysts' expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Insiders Place Their Bets

In related news, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 11,440 shares of the company's stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president directly owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 73,768 shares of company stock valued at $44,122,820 over the last 90 days. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.